Advances in Multiple Myeloma 2024: From Bench to Bedside

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Advances in Multiple Myeloma 2024: From Bench to Bedside

By Dana-Farber Cancer Institute FEATURING Kenneth Anderson

631 views

July 1, 2024

Comments 0

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

3.4K views

8 months ago

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

1.2K views

7 months ago

Multiple Myeloma 101: Diagnosis, Prognosis, and Risk

Dana-Farber Cancer Institute

P. Richardson

693 views

4 months ago

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Insights from 2023 ASH Annual Meeting

H. Hashmi

1.6K views

10 months ago

Whole-Body MRI: Past, Present, and Future

Houston Methodist

N. Gupta

1.7K views

1 year ago

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

616 views

4 months ago

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

135 views

2 months ago

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

729 views

7 months ago

Managing Newly Diagnosed MM in 2024

Indy Hematology Review

S. Usmani

680 views

6 months ago

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

368 views

3 months ago

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies on a …

Insights from 2023 ASH Annual Meeting

A. Jakubowiak

1.4K views

10 months ago

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

619 views

5 months ago

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

401 views

4 months ago

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

M. Kwok

402 views

3 months ago

New

FDA Approval of Isatuximab in 1L MM: Perspectives for Practice

Dana-Farber Cancer Institute

P. Richardson

273 views

1 week ago

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

GRACE

A. Goodman, A. Jeong, S. Rajeeve

2.0K views

1 year ago

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

883 views

7 months ago

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

465 views

8 months ago

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

Insights from 2023 ASH Annual Meeting

R. Banerjee

870 views

9 months ago

ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?"

2024 ASCO® Annual Meeting Insights Hub

O. Landgren

414 views

5 months ago

AUTOPLAY

Login

Login

Join VuMedi

Advances in Multiple Myeloma 2024: From Bench to Bedside

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Optimizing the Management of Patients with Polycythemia Vera (PV)

Recommended

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Multiple Myeloma 101: Diagnosis, Prognosis, and Risk

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key Takeaways"

Whole-Body MRI: Past, Present, and Future

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

HSCT in 2024: What Every Hematologist Needs to Know

Managing Newly Diagnosed MM in 2024

Multiple Myeloma: Not as Simple as "CRAB" Anymore

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies on a …

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

When to Consider Bispecific and CAR-T Therapy in MM

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma

FDA Approval of Isatuximab in 1L MM: Perspectives for Practice

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

MRD Testing in Leukemias: When Negativity Is a Positive Thing

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?"